II. Indications

  1. Seizure Prophylaxis
  2. Second ot thrid line agent in Status Epilepticus

III. Dosing

  1. Start: 500 to 1000 mg/day (max 4000 mg/day) divided twice daily
  2. Titrate every 2 weeks
  3. Target serum concentration: 12 to 46 mcg/ml

IV. Adverse Effects

  1. Agitation
  2. Anxiety
  3. Depressed mood
  4. Dizziness
  5. Fatigue
  6. Irritability
  7. Rash
  8. Somnolence

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

levetiracetam (on 5/31/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
LEVETIRACETAM 1,000 MG TABLET Generic $0.29 each
LEVETIRACETAM 100 MG/ML SOLN Generic $0.04 per ml
LEVETIRACETAM 250 MG TABLET Generic $0.09 each
LEVETIRACETAM 500 MG TABLET Generic $0.10 each
LEVETIRACETAM 750 MG TABLET Generic $0.17 each
LEVETIRACETAM ER 500 MG TABLET Generic $0.40 each
LEVETIRACETAM ER 750 MG TABLET Generic $0.54 each
keppra (on 2/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
KEPPRA 1,000 MG TABLET Generic $0.29 each
KEPPRA 100 MG/ML ORAL SOLN Generic $0.04 per ml
KEPPRA 250 MG TABLET Generic $0.09 each
KEPPRA 500 MG TABLET Generic $0.10 each
KEPPRA 750 MG TABLET Generic $0.17 each
KEPPRA XR 500 MG TABLET Generic $0.40 each
KEPPRA XR 750 MG TABLET Generic $0.54 each

Ontology: Levetiracetam (C0377265)

Definition (NCI) A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
Definition (NCI_NCI-GLOSS) A drug used to treat seizures (involuntary muscle movements) caused by epilepsy (a group of brain disorders). Keppra is being studied in the treatment of seizures in patients with cancer that has spread to the brain. It is a type of anticonvulsant.
Definition (PDQ) A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526173&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=526173&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C47581" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C026098
SnomedCT 323049001, 116076009, 387000003
LNC LP28566-5, MTHU014314
English (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)-, levetiracetam, (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-,(S)-, levetiracetam (medication), LEVETIRACETAM, levETIRAcetam, LevETIRAcetam, Levetiracetam, Levetiracetam (product), Levetiracetam (substance), etiracetam, S-isomer
Spanish levetiracetam (producto), levetiracetam (sustancia), levetiracetam

Ontology: Keppra (C0876060)

Concepts Pharmacologic Substance (T121) , Organic Chemical (T109)
MSH C026098
English levetiracetam (Keppra), keppra, UCB Brand of Levetiracetam, Keppra